VMI
MDGL icon

VHCP Management II’s Madrigal Pharmaceuticals MDGL Stock Holding History

VHCP Management II’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-30,000
Closed -$1.35M – 21
2017
Q3 		$1.35M Buy
+30,000
New +$561K 0.37% 17

Other funds holding MDGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VHCP Management II's MDGL Position: Q4 2017 in Review

VHCP Management II sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2017, closing a stake of 30,000 shares — an estimated $1.35M sold.

VHCP Management II first reported a position in MDGL in Q3 2017 and held it in 1 quarter. The position peaked at $1.35M in Q3 2017. 91 funds tracked by Wall St. Rank hold MDGL as of Q4 2017.

  • VHCP Management II reported no remaining Madrigal Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • VHCP Management II sold 30,000 Madrigal Pharmaceuticals shares in Q4 2017, an estimated $1.35M.
  • VHCP Management II first reported a position in Madrigal Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • VHCP Management II's Madrigal Pharmaceuticals position peaked at $1.35M in Q3 2017.
  • 91 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2017.

Based on VHCP Management II's 13F filing for Q4 2017, filed 13 Feb 2018.